Clearly, therefore, the potential therapeutic use of TSA should take into account the differences in the aggressiveness of breast carcinoma cells and the tumour microenvironment at the secondary growth site, where HGF might contribute to creating a permissive niche for homing. This evidence concerns the gene HGF and neoplasm.